Management ChangeJun 4, 2026, 05:06 PM
Tempest Therapeutics Appoints Two New Directors; CFO Resigns
AI Summary
Tempest Therapeutics announced significant changes to its management and Board of Directors. Nicholas Maestas resigned as Chief Financial Officer, effective June 5, 2026. Concurrently, Justin Trojanowski was promoted to Vice President, Finance, Principal Financial Officer, and Corporate Secretary. Additionally, Dr. John David Yee and Mr. William Drake Richey were appointed as new independent Class II directors, bringing extensive experience in biopharmaceutical and financial sectors, respectively. They will both serve on key board committees and receive equity compensation.
Key Highlights
- CFO Nicholas Maestas resigned from Tempest Therapeutics, effective June 5, 2026.
- Justin Trojanowski was appointed Vice President, Finance, Principal Financial Officer, and Corporate Secretary, effective June 5, 2026.
- Dr. John David Yee was appointed as a Class II director to the Board, effective June 4, 2026.
- Mr. William Drake Richey was appointed as a Class II director to the Board, effective June 4, 2026.
- Both new directors will serve on the Audit, Compensation, and Nominating and Corporate Governance Committees.
- Each new director will receive an initial option award to purchase 25,000 shares of common stock.
Price Impact
More from TPST